KMT2D and serous adenocarcinoma: IGROV-1 displayed alterations in TP53, BRCA1/2, and ATM, which are characteristic of serous carcinomas, but also harbored mutations in CTNNB1, APC, KMT2D, and RB1, more typically observed in endometrioid ovarian cancers.